What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His primary areas of investigation include Internal medicine, Chronic lymphocytic leukemia, Fludarabine, Surgery and Immunology.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Oncology.
In his research, Bioinformatics, Mutation, Cancer research and Lung cancer is intimately related to Cancer, which falls under the overarching field of Oncology.
His Chronic lymphocytic leukemia study improves the overall literature in Leukemia.
His work focuses on many connections between Fludarabine and other disciplines, such as Bendamustine, that overlap with his field of interest in Refractory Chronic Lymphocytic Leukemia.
Michael Hallek works mostly in the field of Immunology, limiting it down to topics relating to Cytotoxic T cell and, in certain cases, FOXP3, Interleukin 2 and Cancer immunotherapy.
His most cited work include:
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines (2519 citations)
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (1433 citations)
- Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. (1170 citations)
What are the main themes of his work throughout his whole career to date?
Michael Hallek mostly deals with Internal medicine, Chronic lymphocytic leukemia, Oncology, Immunology and Cancer research.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery.
His Chronic lymphocytic leukemia study results in a more complete grasp of Leukemia.
He interconnects Venetoclax, Idelalisib, Obinutuzumab and Transplantation in the investigation of issues within Oncology.
His research in Cancer research intersects with topics in Apoptosis, breakpoint cluster region, Tyrosine kinase and CD40.
His study in Fludarabine is interdisciplinary in nature, drawing from both Regimen, Alemtuzumab, Progression-free survival and [email protected]
He most often published in these fields:
- Internal medicine (49.24%)
- Chronic lymphocytic leukemia (36.20%)
- Oncology (29.96%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (49.24%)
- Chronic lymphocytic leukemia (36.20%)
- Oncology (29.96%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Chronic lymphocytic leukemia, Oncology, Venetoclax and Cancer research.
His Obinutuzumab, Rituximab, Ibrutinib and Chemoimmunotherapy study in the realm of Internal medicine connects with subjects such as In patient.
In his study, which falls under the umbrella issue of Chronic lymphocytic leukemia, Neutropenia is strongly linked to Gastroenterology.
His studies in Oncology integrate themes in fields like Idelalisib, Clinical trial, Chemotherapy, Stage and Comorbidity.
His work deals with themes such as Progression-free survival and Tumor lysis syndrome, which intersect with Venetoclax.
Michael Hallek has included themes like Cancer, Phenotype, Tyrosine kinase, B cell and Monoclonal antibody in his Cancer research study.
Between 2017 and 2021, his most popular works were:
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions (205 citations)
- COVID-19 associated pulmonary aspergillosis. (157 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Michael Hallek mainly focuses on Internal medicine, Chronic lymphocytic leukemia, Oncology, Venetoclax and Cancer research.
As part of his studies on Internal medicine, he often connects relevant areas like Gastroenterology.
He combines subjects such as MEDLINE and Minimal residual disease with his study of Chronic lymphocytic leukemia.
His Oncology research includes elements of Cancer, Chemotherapy, Chemoimmunotherapy, [email protected] and Stage.
His research investigates the connection between Venetoclax and topics such as Progression-free survival that intersect with problems in Randomized controlled trial and Hazard ratio.
His Cancer research research incorporates elements of Cell culture, Autocrine signalling and B-cell receptor, B cell.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
